Bellevue Group Ag Autolus Therapeutics PLC Put Options Transaction History
Bellevue Group Ag
- $4.39 Billion
- Q2 2025
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding AUTL
# of Institutions
102Shares Held
173MCall Options Held
0Put Options Held
39.3K-
Blackstone Inc New York, NY20.5MShares$28.5 Million0.22% of portfolio
-
Mak Capital One LLC New York, NY17MShares$23.6 Million5.54% of portfolio
-
Deep Track Capital, LP Greenwich, CT16.9MShares$23.4 Million1.36% of portfolio
-
Syncona Portfolio LTD Guernsey, Channel Islands, X016.6MShares$23.1 Million97.83% of portfolio
-
Armistice Capital, LLC New York, NY12MShares$16.7 Million0.48% of portfolio
About Autolus Therapeutics plc
- Ticker AUTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 90,909,800
- Market Cap $126M
- Description
- Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...